×
antibody humanization

Antibody Humanization & Affinity Maturation Service

Immunogenicity can potentially lead to reduced efficacy through rapid clearance or neutralization of the drug, or toxicity due to cross-reaction with proteins in the body, which can have catastrophic consequences for the patient. Antibody humanization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources and to improve their activation of the human immune system by replacing non-human antibody frameworks with human ones. It is a very important step in therapeutic antibody discovery process.

In some cases that the obtained leads have relative low affinity (such as phage library campaign), or the final application needs extremely high affinity, affinity maturation is required to preserve the epitope specificity and functional activity of the antibody and boost potency to the desired level. In addition, it can be useful to remove potential modification sites for improved developability.

As a one-stop supplier for therapeutic antibody discovery and development, GenScript is proud to offer integrated antibody humanization and affinity maturation service. Combining in silico CDR-grafting, structure-based back mutation, and, supported by our patented FASEBA(Fast Screening for Expression, Biophysical-properties and Affinity) screening, Biacore Surface Plasmon Resonance platform and functional assay platform, the antibody humanization service is offered at GenScript to generate humanized antibody maintaining the affinity and specificity of parental antibody and optimized activity, productivity and thermostability. Seamlessly integrated with humanization, the affinity maturation service will continuously improve the affinity by 10 to 50 folds.

Antibody Humanization & Affinity Maturation Service

Service features

Service specifications

Deluxe Humanization --- Framework Shuffling

  Milestone Deliverables Turnaround
1 Chimeric antibody production, binding confirmation & PTM analysis
  • Sequence, DNA and chimeric ab & top 3 humanized abs (0.5 mg)
  • Guarantee at least 1 ab with affinity comparable with parental ab
14-15 weeks
2 Human acceptor selection, structure-based back mutation library design & construction
3 FASEBA high throughput screening
4 Humanized antibody production & characterization
5 Affinity maturation(Optional)
  • Guaranteed 5-10 fold affinity higher than parental ab
Additional
8-9 weeks

Patented FASEBA screening platform

  • scFv, Fab and various formats humanized
  • 3-D structural modeling
  • Patented screening platform to screen affinity, thermostability, expression level & epitope, no royalty burden
  • Guaranteed delivery of best humanized abs with comparable affinity and good expression level & thermostability
  • Possible to combine with affinity maturation to further improve the affinity by 5-10 fold in <6 months.

Express Humanization --- CDR Grafting

  Milestone Deliverables Turnaround
1 Chimeric antibody production, binding confirmation & PTM analysis
  • Sequence, DNA and chimeric ab & top 3 humanized abs (0.5 mg)
  • Guarantee at least 1 ab with affinity comparable with parental ab
12-13 weeks
2 Human acceptor selection, design & construction of humanized antibody variants(5HC × 5LC/ 4HC × 4LC)
3 Expression and affinity ranking of humanized antibodies
4 Back mutation(Optional)
  • Human framework diversity
  • Fast turnaround time
  • Guaranteed delivery of humanized abs with comparable affinity with parental abs

When using fluorophores, individually or in a multiplex format, it is important to pay attention to a few technical features including:

antibody humanization

Quotation and Ordering

  • Please contact us mentioning "Discovery Biology", our customer service representatives are available 24 hours a day, Monday through Friday to assist you.
 
*
*
*
*